<DOC>
	<DOCNO>NCT00159094</DOCNO>
	<brief_summary>This phase II trial Doxil day 1 vinorelbine day 1 2 woman metastatic breast cancer . Administered every 28 day . A study ass safety efficacy Doxil vinorelbine metastatic breast cancer .</brief_summary>
	<brief_title>A Trial Doxil Multiday Vinorelbine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>PROTOCOL SUMMARY Study design : Phase II trial monthly Doxil® vinorelbine day 1 2 woman metastatic breast cancer . Treatment plan : Patients continue therapy , unacceptable toxicity disease progression . Primary endpoint : Response rate Secondary endpoint : Time progression , overall survival toxicity . Additional study objective : Evaluation treatment-related dyspnea , measurement pulse oximetry drug administration , rigorous study patient experience dyspnea . Palmar-plantar erythrodysesthesia ( PPE ) treat one 2 randomly assign topical salve , measure duration severity symptom . Eligibility : Women prior chemotherapy adjuvant metastatic setting , , 3 prior regimen . Patients one prior regimen metastatic disease must performance status 0 1 ; others may 0-2 . No prior Doxil® vinorelbine therapy . Patients ineligible prior anthracycline dose great 400 mg/m2 , primary anthracycline-refractory disease , disease progression treatment relapse/recurrence within 6 month last dose anthracycline . Patients must normal neurologic , hematologic , renal hepatic functional parameter . Asymptomatic brain metastasis permissible . Treatment plan : Doxil® 40 mg/m2 IV infusion 60 minute day 1 Vinorelbine 15 mg/m2 IV 6 minute day 1 2 Dexamethasone 4 mg IV 8 mg po ( Doxil® pretreatment ) Heparin 5000 U IV ( Vinorelbine pretreatment ) Pyridoxine ( vitamin B6 ) 200 mg po qd Repeat every 28 day . Supportive measure : For anemia ( hematocrit &lt; 35 ) : Procrit® 40,000 U q wk For neutropenia ( ANC &lt; 1,000/mm3 ) : Prophylactic antibiotic ( Cipro® Septra® ) For cycle neutropenic fever/infection grade 3-4 stomatitis : Prophylactic Neulasta® 6 mg SQ day 3 ( This intervention may adopt patient , cycle , 2 first 4 patient enrol need . ) For PPE : randomize 2 topical salve document duration severity sx Dose adjustment : Subsequent cycle give day 29 recovery grade 0-1 toxicity , 3 week delay . Reduce dose drug 25 % grade 3 4 stomatitis palmar-plantar grade 4 thrombocytopenia . Reduce dose Doxil® ONLY 50-75 % abnormal bilirubin , alkaline phosphatase and/or ALT , AST ( appendix 14.3 )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients must inform investigational nature study must give sign inform consent compliance federal institutional guideline . Women 18 year old biopsy proven advance breast cancer . Patients reproductive potential must use adequate contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , barrier device spermicide , surgical sterilization ) treatment three month complete treatment . Performance status ( PS ) 02 ( ECOG ) . PS must 01 patient one prior regimen metastatic disease 2 prior regimen , include adjuvant metastatic . Measurable disease RECIST criterion , baseline staging complete within 14 day registration . At least two week post surgery three week completion irradiation recover toxicity associate treatment . Psychological , family , social geographical condition allow weekly medical follow chemotherapy require . Preregistration blood work must include complete blood count differential , blood chemistry include serum bilirubin , GGT , LDH , SGOT , SGPT , alkaline phosphatase , creatinine , tumor marker , CEA CA 2729 . Patients must : Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Hemoglobin &gt; 8.0 g/dl Serum creatinine &lt; 2.5 mg/dl ( &lt; 200 mol/L ) Serum bilirubin &lt; upper limit normal ( ULN ) SGOT SGPT AST ALT &lt; 2.0 x ULN Alkaline phosphatase &lt; 2.0 x ULN , except attribute tumor Life expectancy &gt; 12 week . Prior Doxil® vinorelbine Cumulative anthracycline dose exceed 400 mg/m2 anthracycline Primary anthracycline refractory disease , ie . disease progression treatment relapse/recurrence within 6 month last dose anthracycline If PS 01 , 3 prior chemotherapy regimen , include adjuvant metastatic If PS 2 , 1 prior regimen metastatic disease 2 prior chemotherapy regimen , include adjuvant metastatic Hormone therapy include aromatase inhibitor within 2 week baseline Pregnant lactate woman . Women reproductive potential must negative pregnancy test must agree use effective contraceptive method Prior history cardiac disease , New York Heart Association Class II great , clinical evidence congestive heart failure Symptomatic brain metastasis Past medical history severe hypersensitivity reaction conventional formulation doxorubicin HCL component Doxil® vinorelbine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>